Jordyn Sava is an assistant editor for Targeted Oncology.
ALPINE Trial of Zanubrutinb Improves PFS vs Ibrutinib in CLL and SLLJanuary 16th 2023
In an interview with Targeted Oncology, Jennifer R. Brown, MD, PhD, discussed the findings from the ALPINE study and the effectiveness of zanubrutinib when used for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Zotatifin With Fulvestrant and Abemaciclib Shows Favorable Activity in ER+ Breast CancerJanuary 12th 2023
In a cohort of 7 patients with ER+ breast cancer, treatment with zotatifin in combination with fulvestrant and abemaciclib led to 2 partial responses and and additional patient with stable disease continuing beyond 24 weeks.
KCd Regimen Does Not Show Non-Inferiority to Autologous HSCT in Multiple MyelomaJanuary 7th 2023
While upfront transplant showed benefit vs carfilzomib, cyclophosphamide, and dexamethasone in the phase 2 CARDAMON study of patients with multiple myeloma, 57.7% of patients achieved at least a very good partial response with the combination.
Review of Myelodysplastic Syndromes Aids Experts in Diagnosing and Treating PatientsDecember 27th 2022
In an interview with Targeted Oncology, Justin Taylor, MD, discussed the recent changes that have been seen with this new classification of MDS and how this review article can help make people more aware of the treatment options available.